From Self-sufficiency
Jump to: navigation, search
File:Estramustine Structural Formulae.png
Systematic (IUPAC) name
(17β)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate
Pharmacokinetic data
Biological half-life 20 hours
CAS Number 2998-57-4
ATC code L01XX11 (WHO)
PubChem CID 18140
DrugBank APRD00625
Chemical data
Formula C23H31Cl2NO3
Molar mass 440.403 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Estramustine (Emcyt, Estracit) is a chemotherapy agent used to treat prostate cancer. It is a derivative of estrogen (specifically, estradiol) with a nitrogen mustard-carbamate ester moiety that makes it a alkylating antineoplastic agent similar to mechlorethamine, with estrogen-induced specificity.

Estramustine is marketed in the United States by Pharmacia (now a subsidiary of Pfizer)

Clinical uses

Estramustine is indicated for the palliative treatment of metastatic and/or progressive carcinoma of the prostate.


Fex, H. J.; Hogberg, K. B.; Konyves, I.; Kneip, O. J.; 1967, U.S. Patent 3,299,104.

External links


es:Estramustina pl:Estramustyna